Accredited webinar: Bridging gaps in PTLD care

Accredited: Webinar

Stay up to date with the latest approaches to managing posttransplant lymphoproliferative disorder (PTLD) with Nina Babel (Germany), Daan Dierickx (Belgium), Sylvain Choquet (France), and Susan Prockop (USA). In this EBAC-accredited webinar, our expert panel discuss:

• Confirming and classifying PTLD: The role of histology and EBV status
• Risk stratification and escalation planning after PTLD diagnosis
• Anticipating second‑line PTLD care: Evidence, access, and referral timing
• Multidisciplinary team coordination for timely escalation and referral in PTLD

Earn up to 15 minutes of effective education time upon successful completion of each video. To earn 1 CME credit, watch all four videos and then complete the knowledge assessment and evaluation form.

Meet the experts

Nina Babel, MD, PhD

Nina Babel is Principal Investigator at the Berlin Institute of Health, Center for Regenerative Therapies, Charité, and head of the Institute of Clinical Immunology and Outpatient Clinic for Immunodeficiency at the Ruhr University Bochum, Germany. She has clinical training in internal medicine, nephrology/transplant medicine, and immunology, and the focus of her outpatient clinic is primary and secondary immunodeficiency, including postinfectious syndromes.

Disclosures: Honoraria from Pierre Fabre for an educational lecture at the European Society for Organ Transplantation (ESOT) in 2023.

Daan Dierickx, MD, PhD

Daan Dierickx is a hematologist at University Hospitals Leuven (UZ Leuven), Belgium, and a researcher within the Department of Oncology at KU Leuven and the Leuven Cancer Institute. He leads research focused on lymphomas arising in immunocompromised patients, including PTLD, and is involved in translational and clinical research aimed at improving the diagnosis and management of hematologic malignancies. Dierickx has extensive expertise in lymphoma, transplantation-associated hematologic complications, and novel therapeutic approaches in hematology.

Disclosures: Atara Biotherapeutics, Incyte, Kite, Pierre Fabre, and Takeda.

Sylvain Choquet, MD

Sylvain Choquet is Head of the Clinical Hematology and Cellular Therapy Unit at Pitié-Salpêtrière Hospital (AP-HP), Sorbonne University, Paris, France. He is President of the CANCEROGREF network, which focuses on post-transplantation cancers, and President of the AP-HP Drug Committee in Onco-Hematology. Choquet is also a member of the scientific committees of the Onco-VIH network, dedicated to cancers in people living with HIV, and the LOC network for central nervous system lymphoma. His clinical and research interests include PTLD, lymphoma, and malignancies arising in immunocompromised populations.

Disclosures: Consultancy fees and/or honoraria from AbbVie, AstraZeneca, Amgen, BeOne, Gilead/Kite, Johnson & Johnson, Lilly, Novartis, Pierre Fabre, SERB, and Takeda.

Susan Prockop, MD

Susan Prockop is Associate Professor of Pediatrics at Harvard Medical School and Director for Clinical and Translational Research in the Stem Cell Transplant Program at the Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Massachusetts, USA. She is a pediatric stem cell transplant attending physician whose primary clinical focus is the care of patients with immune deficiencies and immune dysregulation. Her clinical research focuses on immune reconstitution and its contribution to the control of viral infections. She has expertise in conducting clinical trials involving complex cellular products, including genetically engineered products.

Disclosures: Support for the conduct of clinical trials through Boston Children’s Hospital from Cabaletta Bio and Pierre Fabre. Inventor of intellectual property related to a third-party VST program, with all rights assigned to MSKCC. Consulting fees from ARScinec, Atara Biotherapeutics, DSMB Stanford University, Ensoma, HEOM, Mesoblast, NYBC, and Pierre Fabre. Equity share, Regatta Bio.